Citron cites the competitive threat from liquid biopsies and slowing test volume growth for Cologuard.
Previously: Exact Sciences under pressure on potential CRC blood screening test; shares down 9% (Jan. 17)
Previously: Exact Sciences to expand capacity to 4.5M Cologuard tests/year (Nov. 8, 2017)
Now read: Here's Why Biotech Stocks Got Smashed »
Subscribe for full text news in your inbox